Apart from ibrutinib, people with M-CLL, devoid of TP53 aberrations and in good shape plenty of to tolerate FCR therapy, should still be excellent candidates for the latter, with the benefit remaining this cure may be concluded in 6 months when ibrutinib has to be taken indefinitely. This option mig